Baird conducted a follow-up survey of retina specialists following the safety alert for Appelis Pharmaceuticals Syfovre. The survey suggests most doctors continue to use Syfovre, but they are keen to learn more about the cause, rate, and patient characteristics of these events suggesting a cautious but not totally bearish view. Baird maintains its Outperform rating and $115 price target on Appelis Pharmacuetical shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis price target lowered to $53 from $76 at Wells Fargo
- Apellis price target lowered to $72 from $100 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Stifel ‘cautious but not fatalistic’ about Syfovre, reiterates Buy on Apellis
- Unusually active option classes on open July 18th